| | |
| Legal status | |
|---|---|
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C22H23N3O2 |
| Molar mass | 361.445 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
BZO-CHMOXIZID (CHM-MDA-19) is a synthetic cannabinoid compound first reported in 2008 in the same series as the better known derivative MDA-19. [2] It started to be widely sold as an ingredient in grey-market synthetic cannabis blends in 2021 following the introduction of legislation in China which for the first time introduced general controls on various classes of synthetic cannabinoids, [3] but did not include the group to which MDA-19 and BZO-CHMOXIZID belong. While BZO-CHMOXIZID is the most potent compound at CB1 from this so-called "OXAZID" series, it is still markedly CB2 selective and of relatively low potency at CB1, with an EC50 of 84.6 nM at CB1 compared to 2.21 nM at CB2. [4] [5]
In the United States, As of October 20, 2024 BZO-CHMOXIZID is legal at the federal level, but may be considered illegal if intended for human consumption under the federal analogue act. [6]
North Dakota has placed BZO-CHOMXIZID (CHM-MDA-19) (along with BZO-HEXOXIZID (MDA-19), BZO-POXIZID (Pentyl MDA-19), 5F-BZO-POXIZID (5F-MDA-19) and BZO-4en-POXIZID (4en-pentyl MDA-19) into Schedule I on 04/27/23. [7]
In China, the May 2021 ban on specific synthetic cannabinoid core classes does not include the class of cannabinoids BZO-CHMOXIZID belongs to. [8] [9]